Biocure Technology Inc.
CUREX
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -99.79% | -77.09% | -96.90% | -38.71% | -13.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -99.79% | -77.09% | -96.90% | -38.71% | -13.31% |
| Operating Income | 99.79% | 77.09% | 96.90% | 38.71% | 13.31% |
| Income Before Tax | 75.00% | 94.87% | 92.18% | -100.74% | 71.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.00% | 94.87% | 92.18% | -100.74% | 71.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.00% | 94.92% | 92.18% | -100.75% | 92.40% |
| EBIT | 99.79% | 77.09% | 96.90% | 38.71% | 13.31% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 76.47% | 94.93% | 88.89% | -100.91% | 91.10% |
| Normalized Basic EPS | 72.73% | 76.19% | 83.33% | 79.17% | 50.00% |
| EPS Diluted | 76.47% | 94.93% | 88.89% | -100.91% | 91.10% |
| Normalized Diluted EPS | 72.73% | 76.19% | 83.33% | 79.17% | 50.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | -10.04% | -18.33% | -13.70% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | -10.04% | -18.33% | -13.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |